Research Papers:

Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor

Yang Fu, He Hao, Luwei Guo, Ge Yang and Xiefu Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:10136-10144. https://doi.org/10.18632/oncotarget.14359

Metrics: PDF 1921 views  |   HTML 1859 views  |   ?  


Yang Fu1,*, He Hao1,*, Luwei Guo1, Ge Yang2, Xiefu Zhang1

1Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

2Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

*These authors have contributed equally to this work

Correspondence to:

Yang Fu, email: [email protected]

Xiefu Zhang, email: [email protected]

Keywords: GIST, intermediate-risk, imatinib, retrospective analysis, RFS

Received: September 30, 2016     Accepted: December 13, 2016     Published: December 29, 2016


Background & Aims: A significant benefit of imatinib adjuvant therapy for patients with high risk gastrointestinal stromal tumors (GIST) has been confirmed. However, the effect of imatinib adjuvant therapy for intermediate-risk GIST has not been well studied. In this article, we compare differences of recurrence-free survival (RFS) rates between patients with intermediate-risk GIST who accepted imatinib adjuvant therapy and those who did not.

Method: A retrospective study of intermediate-risk GIST was conducted in the First Affiliated Hospital of Zhengzhou University, China. The pathology reports of 112 patients who had been treated by surgery showed intermediate-risk GIST. The treatment and control groups were designed according to the administration of imatinib adjuvant therapy (≥1 year). Survival and recurrence data were collected and RFS of each group was calculated.

Results: Eighty fivepatients with intermediate-risk GIST were followed up. Thirty of them (treatment group) accepted imatinib adjuvant therapy over 1 year. Through comparing the RFS of the two groups, we established that there was no statistically significant difference in RFS rates (P=0.940).

Conclusion: There is no significant benefit for patients with intermediate-risk GIST to accept imatinib adjuvant treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14359